Asia in the ageing century: part III - healthcare by Rafal Chomik
  
 
 
 
 
Asia in the ageing century:  
Part III – Healthcare 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CEPAR research brief 2013/03 
 
  
 
 
 
 
 
 
 
 
 
  
 
    Summary 
 
 
 
 
 
  
 
• This is the third research brief in a three-part series that looks at Asia in the ageing 
century, with a particular focus on the countries of East and South-East Asia. 
 
• The context is outlined in the first brief, which describes population, urbanisation 
and social trends in the region. Specifically, it notes that population ageing in East 
and South-East Asia is happening faster and at a lower level of economic 
development than in the West. Many Asian countries now have a decade or so to 
prepare for the final stages of demographic transition. Parts II and III of the series 
focus on two areas of economic activity which are both pertinent to population 
ageing and have enormous scale: provision of retirement income (covered in Part II) 
and of healthcare (outlined in the present brief).   
 
• As Asian societies become wealthier and older they will demand more of their health 
systems. This translates to extending health insurance coverage to a broader cross-
section of the population, and offering reimbursement for a greater proportion of 
costs on a larger package of benefits. China has enrolled 1.2 billion people into the 
health insurance system within the last decade but in some provinces benefit 
packages are lacking. Malaysia achieved universal health coverage in the 1980s, but 
in 2004 key medicines were only available in a quarter of public health facilities. 
 
• East and South-East Asian governments currently have the fiscal capacity to keep 
expanding health systems, but to avoid the excessive cost growth seen in the West 
they will need to employ various micro, macro and demand-side measures – heeding 
the successes and failures of reforms within the region and elsewhere.  
 
• An important area for healthcare is the epidemiological transition that comes with 
ageing societies, where the relative prevalence of non-communicable diseases 
increases. Health packages in Asia are yet to take a full account of this change.  
 
• Health spending in the region was worth over US$1 trillion in 2010. On the 
financing side, private health insurance is still a niche market making up US$50 
billion of spending, but recent growth has been high (e.g. 100% p.a. in China). On 
the provider side, the size and growth of the market will result in opportunities for 
pharmaceutical, medical device manufacturing and consumer health companies, as 
well as for operators of hospitals and specialised facilities. Some of that demand will 
spill over into the growing medical tourism market.  
 
• At the level of the macro-economy, stronger welfare provision offers an opportunity 
to rebalance growth in the region by reducing excessive precautionary savings. So 
far, East and South-East Asian countries have been taking this opportunity but much 
remains to be done for healthcare systems to be fully ready for an ageing population. 
 
 
 
 
 1 
 
1. Introduction 
  
Richer and better-educated populations across Asia will demand more from their 
health systems than they have in the past. It is now clear that developments in 
this field will not merely involve a transition from poor to rich or from low to 
high levels of health spending.  
 
Changes will be layered with demographic and epidemiological dimensions, 
requiring specific responses and providing unique opportunities in financing, 
provision, and trade in the health sector. In most cases, the speed of Asia’s 
demographic transition will dictate a level of healthcare development that is 
more advanced at a given level of income than was necessary in the evolution of 
western national health systems.  
 
This is the final brief in a three-part series that looks at ageing in the Asian 
century, with a particular focus on the countries of East and South East-Asia 
Asia, but with contrasting comparisons to key regional countries such as India 
and Australia. Part I set the demographic context, showing that the scale and 
speed of ageing and urbanisation in the region is unprecedented, and that levels 
of labour mobility and weakening social institutions are eroding familial support 
networks.  
 
Part II and III of this series look at the necessary responses and potential 
opportunities arising from Asia’s population ageing. The second brief 
considered retirement income systems; here, we look at healthcare.  
 
Not only are these two sets of topics pertinent to population ageing, they have 
enormous scale. They also represent a macro-economic opportunity to rebalance 
growth across Asia – allowing individuals to pool idiosyncratic risks associated 
with income and health shocks and reducing the need for households’ excessive 
precautionary savings (Chamon and Prasad, 2008, Baldacci et al., 2010). 
 
2. Systems in transition 
 
Asia’s health systems have diverse origins, levels of development and expected 
trajectories. This heterogeneity is, for example, apparent in the range of health 
outcomes proxied by average life expectancy – from 64 in Cambodia to 84 in 
Japan. At the cost of some oversimplification, it is possible to classify these 
systems using the same types of categories into which one might group a set of 
economies: developing, emerging and advanced (e.g., see Kanzler and Ng, 
2012). The classification corresponds to the level of spending on healthcare as 
well as income per capita, which are highly correlated (see Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite the 
diversity of Asia’s 
health systems, we 
can try to classify 
them 
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Figure 1. Classifying health systems 2010 
 
Source: WHO (2013); World Bank (2013)  
 
Health systems which are in the ‘developing’ category, including those of 
Cambodia, India, Indonesia, Pakistan, the Philippines, and Vietnam, can be 
characterised by high out-of-pocket costs, poor use of technology, low and 
uneven coverage of financing and service availability, inadequate preventative 
care, and inequality in the health status of the population.  
 
Emerging health systems, including those of China, Malaysia, and Thailand 
share some of these characteristics but to a lesser degree; for example, access to 
services can still be variable. In addition, emerging systems experience growing 
levels of private insurance and medical tourism, particularly in Malaysia and 
Thailand. Both developing and emerging systems face challenges relating to the 
dual burden of infectious as well as non-communicable diseases (see Section 6). 
All countries, but particularly those with advanced health systems, are 
experiencing public cost increases as an area of concern. 
 
All these elements are coloured by the changing demographics. Increasing costs 
are being driven by greater use of costly technology, higher levels of utilisation, 
as well as growing elderly populations. Older people, especially the older-old, 
have higher rates of disease; health treatments for older people are on average 
more expensive than those for younger people; and the decreasing size of 
families and level of cohabitation means that a greater proportion may rely on 
public financing rather than private, familial support.  
 
Countries which are further advanced with demographic transition may be 
thought of as a model for the still younger, emerging countries in designing 
effective healthcare systems. Japan, for example, has the oldest population in the 
world but its health system is still one of the most efficient and, compared with 
developed countries, one of the cheapest. 
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Table 1. Summary of health financing in selected countries 
 Public Pop 
cover 
Costs 
cover 
Benefit cover / Access issues Private 
market 
Australia • Tax financed Medicare (1984) 
 
100% 68% • Hospitals and medical service 
free/subsidised 
• Ancillary at public hospitals 
• Medicine purchase scheme to lower 
costs + subsidies for poor 
$11.4b 
China • Urban Employee Basic Medical 
Insurance (1998;mandatory) 
• Urban Residents Basic Medical Insurance 
(2007; voluntary) 
• New Rural Cooperative Medical Scheme 
(2003; voluntary) 
• Medical Financial Assistance covers 
premiums/extra costs of rural poor 
95% 54% 
but 
varies 
by area 
• Mostly catastrophic and inpatient care 
• Tiered public hospitals 
• Median availability of selected generic 
medicines: 18% in 2006 
• Decentralised, with variable benefit 
packages, access and quality 
• Oversubscribed/wait periods 
$29.5b 
Hong 
Kong 
• Tax financed Dept of Health and Hospital 
Authority 
100% 29% • Hospitals /medical: free/subsidised 
• But long waiting periods 
$1.1b 
India • Employee State Insurance Corporation 
(1948) 
 
low 49% • Medical free/subsidised through 
tiered hospital system 
• Median availability of selected generic 
medicines: 21% in 2004 
• Oversubscribed/waiting lists 
• Variable access and quality 
$6.6b 
Indonesia • Jamsostek Medical Scheme (1992). 
Mandatory for employees unless they 
have better private cover 
• Jamkesmas (2004) tax funded for poor  
• Askes for public sector 
63% 83% • Jamkesmas medical free at public or 
private hospitals, and generic 
medicines at special pharmacies 
• Variable access and quality 
• Median availability of selected generic 
medicines: 47% in 2004 
$2.3b 
Japan • Employees Health Insurance (1961) for 
employees and families 
• National Health Insurance for others 
• Integrated aged care/healthcare for older 
100% 46% • Universal access to any facility: public 
and private hospitals / clinics (for-
profit hospitals don’t exist) 
$16.3b 
Korea • National Health Insurance (1977) for 
employees, subsidised by Medical Aid 
Programme for others 
100% 56% • Free choice of facilities, almost 
entirely by private providers 
$6.6b 
Laos • Health insurance for employees and 
family 
Low 35% • Medical through hospitals 
• Excludes vehicular road traffic 
accident and cosmetic treatment  
n/a 
Malaysia • Tax financed system run by Ministry of 
Health (1957)  
100% 36% • Medical care in hospitals and clinics  
• Medicine subsidised 
• Median availability of selected generic 
medicines: 25% in 2004 
$1.1b 
Philippin. • National Health Insurance Programme 
(1995) for formal employees 
• Sponsored Programme (1996) for poor  
• Individually-Paying Programme (1999) 
for informal and self-employed 
• Overseas and retiree programmes  
82% 75% • Benefits on schedule up to a ceiling 
• Medical and hospitals provided at 
different govt levels 
• Median availability of selected generic 
medicines: 15% in 2005 
$0.8b 
Singapore • Medisave (1984) – mandatory savings 
• MediShield (1990) – group insurance 
• Medifund (1993) means-tested cover 
• ElderShield (2002) for aged care 
100% 38% • Heavily subsidised hospitals  
• Medisave used for basic treatment 
• Serious treatment from Medishield 
• Medifund covers deficit beyond 
Medisave/Medishield /own means 
$0.8b 
Thailand • Civil Servant Medical Benefit Scheme 
• Social Security Scheme (1990)  
• Universal Coverage Scheme (2001) - 
formerly 30-Baht Scheme for poor 
99% 68% • Basic medical and hospital  
• Median availability of selected generic 
medicines: 75% in 2006 
$1.4b 
Vietnam • Compulsory Health Insurance (2009) 
with tax financing for poor 
• Voluntary Health Insurance (2009) 
65% 54% • Basic inpatient/outpatient package 
• Variable access and quality 
$0.3b 
Source: Swiss Life (2012); WHO (2013); China’s Ministry of Health (2012); Barber and Yao (2010); UHC Forward (2013); 
European Observatory on Health Systems and Policies (2013); government health insurance provider web sites; 
Author’s calculations. Note: Dates denote scheme inception. Private sector insurance market based on value of 
prepaid premiums in US$ in 2010. Costs cover relates to public sector expenditure as proportion of total health 
expenditure – it may be different essential healthcare since above figures may reflect levels of discretionary health 
spending (e.g., in Japan public cover for essential treatment is 70-90%). 
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China can also act as a model for other developing countries. It has achieved 
near universal coverage at a fraction of the income of countries that have put it 
in place in the past and at an unprecedented pace.  
 
3. Health insurance coverage 
 
The coverage of a country’s health insurance system has several dimensions. 
The most popular meaning refers to the proportion of the population insured by 
the scheme. Advanced countries (with the notable exception of the United 
States) and many emerging countries have reached universal coverage. This 
ensures that all or almost all citizens are entitled to some level of health care.  
 
But even where the whole population is covered by health insurance, the depth 
or scope of the benefits package that is available through the system – or the 
proportion of costs covered – may be limited. The concept is demonstrated 
visually in Figure 2. Furthermore, effective coverage can be poor despite the 
official level of entitlement, for example, when clinics are far away. Malaysia 
may have achieved universal health coverage in the 1980s, but in 2004 key 
generic medicines were only available in a quarter of public health facilities.  
 
Figure 2. Conceptual model of health insurance coverage 
 
Source: Busse and Schlette (2007) 
 
Table 1 summarises the main public health insurance systems in place and the 
extent of their coverage across selected Asian countries. Countries with 
emerging health systems, such as India, Indonesia, Laos, Philippines, and 
Vietnam still have low levels of coverage, though some, such as the Philippines 
and Vietnam are en route to achieving universal levels.  
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Figure 3. Coverage and financing  
  
B. Cumulative population covered by public health insurance, China, 2001-2011 (millions) 
 
 
 
Source: Busse and Schlette (2007); China’s Ministry of Health (various); WHO (2013); Soto et al. (2012); Note: OOP 
denotes Out-Of-Pocket costs. Excess cost growth relates to increases in cost of health due to non-demographic 
factors (e.g., technology, utilisation). 
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Countries with tax-financed systems, such as Malaysia, tend to have more 
comprehensive coverage, compared to those with social health insurance 
coverage, where only formal sector employees have traditionally been covered 
(Figure 3.A).  
 
China’s expansion of health coverage has been staggering. It has enrolled 1.2 
billion people into the health insurance system within the last decade and 
coverage for rural citizens increased from near-zero to almost universal in the 
space of just five years (Figure 3.B.). Much of this has been the result of the 
central government subsidising local governments and decentralising decision-
making rather than mere mandate. While successful in covering the population, 
it has meant uneven benefit packages across provinces (Barber and Yao, 2010). 
 
Filling out the box in Figure 2 to a level that is financially sustainable is often 
the stated aim for health systems. Governments that have achieved universal 
coverage are now looking to improve the generosity of their respective systems, 
in particular, reducing high out-of-pocket costs. For example, out-of-pocket 
spend was nearly 40 per cent of total health expenditure in Indonesia and China, 
compared to 14 per cent in Thailand and Japan (Figure 3.A).  
 
Yet, reducing private spending is not uniformly pursued by all governments. For 
example, Singapore aims to foster personal responsibility for health: while it 
offers extensive subsidies within the public system, it has instituted a 
compulsory, tax-deductible savings scheme from which families must pay a 
varying proportion of costs or purchase their own private health insurance.  
 
4. Containing costs 
 
The increase in health expenditure resulting from improvements in coverage, 
technology and ageing is replete with challenges and opportunities. The IMF, in 
Soto et al. (2012), estimates that in the next 20 years public health spending in 
Asia will see an increase of between 0.5 per cent of GDP in Pakistan and 5.5 per 
cent of GDP in Korea (Figure 3.C), with more than half of that increase due to 
population ageing. While OECD countries are expected to see higher 
proportional levels of growth than emerging Asia, the projected GDP growth in 
the latter translates to a considerable amount of money in absolute terms. 
China’s Ministry of Health (2012) notes that between 1978 and 2011 the average 
annual real growth rate of total health expenditure was over 11 per cent, well 
above annual GDP growth. 
 
The IMF believes that emerging economies have the fiscal space to increase 
health expenditure, but warns that this be done in a “fiscally sustainable manner 
while avoiding the inefficiencies and resulting high costs of the health systems of 
advanced economies” (Gupta et al., 2012, p7).  
 
 
 
 
 
 
Extending coverage 
and lowering out-
of-pocket costs can 
be done in a 
number of ways 
 
 
 
 
 
 
 
 
 
 
 
 
In Singapore, for 
example, there is 
greater onus on 
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Bigger health 
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result in greater 
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But while Asia can 
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So how can governments restrain health costs? There are a number of macro, 
micro and demand-side measures that various countries have implemented with 
varying degrees of success (Tyson et al., 2012; Jenkner et al., 2012). These are 
summarised in Table 2, and range from budgetary caps to introducing co-
payments.  
 
Table 2. Measures for containing healthcare costs 
Macro-level controls Budget caps Limits on overall or subsector spending (e.g., hospital budgets or GP 
expenditure ceilings) 
Supply constraints Limiting volume of inputs or outputs in healthcare (e.g., GP numbers, 
controlling the pharmaceuticals or benefits schedule) 
Price controls Regulating prices (e.g., wages, reference pricing of pharmaceuticals or 
benefits, payment by capitation or Diagnosis Related Group (DRG)) 
Micro-level reforms Public management 
and coordination  
Organisational changes to improve accountability, incentives, or 
reduce overlap (e.g., fewer management levels, gate-keeping by GPs 
to screen out unnecessary specialist treatment) 
Contracting Changing arrangements with physicians, hospitals and other providers 
(types are: salaries or budgets, capitation or DRG, fee-for-service) 
Market mechanisms Introducing market mechanisms between supply and demand side to 
stimulate competition (e.g., internal market of GPs buying services 
from hospitals, separating financing and provision, patient choice) 
Demand-side reforms Increasing share of costs borne by patients (e.g., lump sum or co-
payments, tax treatment of private health insurance) 
Source: Adapted from Oxley and MacFarlan (1995) and IMF (2010) 
 
Japan has been very successful in using price controls across the entire health 
system to keep costs down, while Thailand has been a regional leader in moving 
from fee-for-service payments to location-specific caps, hospital budgets, and a 
Diagnosis Related Groups system of reimbursement. China follows other 
countries in announcing a pilot to use collective market power and negotiate 
pharmaceutical contracts at a provincial level (Government of People’s Republic 
of China, 2012). 
 
Future-proofing health systems against population ageing will require more 
work, however. Even though Japan is thought to have a successful health 
system model, it still suffers from poor incentives and over-utilisation issues. 
Even excluding long-term care costs, elderly Japanese (aged 65+) are 
responsible for per capita health expenditure that is four times that of the rest 
of the population (Li, 2012). 
 
5. Role of private sector 
 
Differences in the level of development, values and political priorities will 
influence how much prominence countries place on private sector involvement 
in healthcare. Yet private sector financing has its benefits in limiting public 
expenditure, supplementing basic socialised coverage, reducing Out-Of-Pocket 
expenses, and stimulating the supply of more advanced, specialised treatments. 
Based on the conceptual framework in Figure 2, private health insurance allows 
us to expand the breadth, depth and height of the box. 
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out-of-pocket 
expenses 
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Private health insurance in the region is still a relatively niche market, worth an 
estimated US$50 billion in 2010 across East, South-East and South Asia (see 
Table 1; total excludes Australia and Japan). More than half of that is attributed 
to China, which saw the value of private health insurance revenues 
approximately double each year between 2008 and 2011.   
 
With appropriate regulations in place, the benefits of an active private sector 
health insurance market can be reaped while limiting inequality. Examples of 
these regulations include fixed private insurance premiums for basic coverage 
that encourage competition on quality rather than cost, mandatory acceptance of 
all patients regardless of pre-existing conditions, and the creation of risk funds 
that equalise risk across insurers and therefore reduce the targeting of low-risk 
populations (Kanzler and Ng, 2012; also, see Box 1 about related modelling). 
 
As noted in Section 4 and Table 2, private sector involvement is one way to 
introduce market mechanisms to drive efficiency and innovation – the third 
wave of reforms in the development of the health system (following reaching 
universal coverage and pursuing rationing and expenditure caps; Cutler, 2001). 
Thailand is one example. Viriayh, one of its established private health insurers, 
has recently developed micro-insurance products to meet the demands of the 
lower-income population within the universal healthcare system. It has been 
rewarded for its success. In 2009, it recorded growth of over eight per cent 
compared to the three per cent average in the Thai non-life insurance industry 
(International Insurance News, 2010).  
 
But private insurer competition must be managed correctly to avoid the pitfalls 
seen in the dysfunctional market in the USA, where the proliferation of insurers 
weakens their individual market power to negotiate with providers and results in 
increased costs (Porter and Teisberg, 2006). In general, a greater share of private 
insurance across OECD countries is associated with lower non-demographic cost 
increases (Tyson et al., 2012) 
 
Private sector involvement can come in different forms. In addition to acting as 
payors themselves, private institutions can help public health insurers in 
purchasing, claims processing, IT, quality control and cost control under 
competitive contracting. Taiwan has managed to run its national health insurance 
with administrative costs accounting for only 1.3 per cent of the budget thanks to 
effective use of health information technology (Cheng, 2012). 
 
Encouraging private payors to run health facilities, including physician 
networks, could create incentives to improve provider quality and efficiency 
(Kanzler and Ng, 2012). China has pledged to double the patient volume at 
private hospitals, which make up a third of the country’s hospital stock, during 
its current five year plan (Government of People’s Republic of China, 2012). If 
 
But the sector is 
still nascent 
 
 
 
 
 
 
 
 
 
 
 
 
 
It can also improve 
efficiency and 
reduce costs if 
managed correctly, 
and private market 
entrants can reap 
some of the 
rewards 
 
 
 
 
 
 
 
 
 
 
 
 
Aside from 
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provision  
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this involves large-scale privatisations, it may be a possible route into Chinese 
healthcare for private investors.  
 
Box 1. CEPAR research spotlight: Private health insurance over the lifecycle 
A well-functioning private health insurance system alongside universal health 
insurance may reduce cost pressures on the public systems and improve overall 
efficiency. Yet the prominence of private health insurance differs greatly across 
countries, not least because governments impose different regulatory 
mechanisms and incentives to protect those who may otherwise be priced out of 
the market. 
In the first paper of its kind, CEPAR research fellow, Elena Capatina, with 
Minchung Hsu and Gary Hansen (forthcoming) study the interaction between 
public and private insurance in a general equilibrium, life-cycle framework. 
They develop a life-cycle model of individual decision-making based on 
outcomes seen in several, mostly, OECD countries (Korea, Japan, and Taiwan 
are included in the study) and show that the interactions between health and 
labour income risk during working life and between health risk and bequest 
motives during retirement are important in shaping the demand for private 
health insurance.  
They also look at the implications of several government policies and 
regulations of private health insurance markets, focusing on the effects of 
subsidies and of regulation preventing discrimination based on health status, as 
well as how other government programs such as social security distort the 
incentives of different age groups to purchase private health insurance.  
 
The total health sector spending in East and South-East Asia was worth over 
US$1 trillion in 2010. That level of expenditure allows ample opportunities for 
providers, from private hospitals to specialised facilities, IT providers (see box 
3), pharmaceuticals and consumer health. Greater competition in the provider 
market has the potential to lower costs for public and private payors. 
 
The East and South-East Asian market for medical devices, medical imaging, 
and diagnostics was worth about a third of the global market, at around 
US$100 billion (Frost & Sullivan, 2011). It is predicted that Asian markets will 
overtake those of Europe and North America within 15 years, presenting 
advanced economies such as Australia, which are integrated in the region, a 
significant advantage. At present, Australian companies excel in very niche 
markets. Only seven per cent of medical technology patents filed in Australia 
in 2007 were by Australian companies, indicative of a dominance of foreign 
players (Griffith Hack, 2010). 
 
Healthcare market growth seen in recent years is naturally not guaranteed to 
continue, and foreign entrants will want to take a long view on investment as 
Asian healthcare budgets reach advanced economy levels and as the 
demographic shift takes place. In the meantime, the advice is that companies 
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sector should take 
the long view 
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wishing to explore the market think about local partnerships, build creative 
business models to reach diverse market segments and engage, where possible, 
with the various, decentralised layers of government (Le Deu et al., 2012).  
 
6. Changing needs 
 
Demographic changes described in this paper are coupled with, and in many 
ways linked to, the epidemiological transition. This trend involves an adjustment 
of the burden of disease from infectious to non-communicable diseases (NCDs; 
see Singapore in Figure 4.A, for an example). NCDs are often those associated 
with lifestyle, urbanisation and ageing, and include cardiovascular disease, 
cancer, chronic respiratory diseases, and diabetes.  
 
Like other parts of the world, even as overall mortality rates have decreased, 
Asia has experienced a rapid relative increase in the prevalence of NCDs leading 
to considerable human and economic costs (Abegunde, 2007). According to the 
International Diabetes Federation (2012) there are already some 125 million 
diabetics in East Asia and the Pacific, which has seen rates quadruple since the 
1970s, and China reports to have a total of 260 million people diagnosed with 
various chronic diseases (China’s Ministry of Health, 2012).  
 
The region faces a double burden of disease, where NCD rates are increasing 
even as communicable diseases are still prevalent. Indeed, vulnerable 
populations are the hardest hit, with NCD related death rates inversely 
proportional to GDP (Dans et al., 2012). 
 
Even though the age- and sex-specific burden of disease from chronic illness, 
measured by financial cost, mortality or morbidity, may be expected to decline, 
the demographic profile of populations will mean that total burden of non-
communicable disease will likely increase across all regions (except possibly for 
lung cancer). 
 
There are some significant implications. In terms of financing, it will be 
important to design essential benefit packages that include NCD screening and 
treatment. Screening and response capacity will also need to be strengthened 
across the region. Currently, the availability of key NCD tests in the public 
system and medicines at primary healthcare level are limited in many Asian 
countries (Figure 4.B).   
 
There is also a public health imperative to focus on preventative care and 
managing lifestyle factors (See Box 2). For example, strategies to reduce salt 
intake and control tobacco in emerging countries can cost as little as US$1-2 per 
person and avert millions of deaths and billions of dollars of loss in economic 
output (Lim et al, 2007).  
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breadth of 
coverage and levels 
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Figure 4. Epidemiological transition 
 
B. Proportion of key Non-Communicable Diseases tests available in public health system and 
medicines available at primary healthcare level, 2010 
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Source: Chongsuvivatwong et al. (2011), WHO (2013); Note: Based on availability of 17 medicines (insulin, aspirin, 
metformin, glibenclamide, thiazide diuretic, ACE inhibitors, CC and beta blockers, tamoxifen, statins, oral morphine, 
nicotine patches or gum, salbutamol, prednisolone tabs, steroid inhalers, hydrocortisone injections, ipratropium 
bromide) and 7 tests (peak flow measurement spirometry, total cholesterol measurement, electrocardiogram,  
diabetes testing, palpation or mammogram, bowel cancer screening (digital or colonoscopy), and cervical cytology. 
 
 
Developing institutional capacity for research can be one early tactic. The 
successes of the Thai health system in tackling NCDs may in part be the result of 
investment in research and health promotion directly funded by tobacco and 
alcohol taxes.  
 
Indeed, there are strands of research in this area that remain unexplored. For 
example, the relationships between urbanisation and the health of a population 
are well known, but there is far less knowledge about the health effects of urban 
living on an ageing population (Black et al., 2011). 
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Box 2. CEPAR research spotlight: Chronic illness management 
 
Many patterns of illness confronting ageing populations are avoidable and can 
even be reversed with appropriate lifestyle changes. This is often referred to as 
‘healthy ageing’ and can mitigate the expected increases in health expenses. 
CEPAR Associate Investigator, Colette Browning, with colleagues at Peking 
and Monash universities and in the Beijing government, has been conducting a 
study related to such a chronic illness management system in China. It is work 
based on previous research conducted in Australia. 
 
As part of the initiative, known as the Happy Life Club, doctors and nurses are 
trained to change the behaviour of people with chronic conditions by way of 
motivational interviewing techniques. Initially, the Happy Life Club 
intervention was conducted in a large residential area of Beijing, but has now 
been extended to a larger district of Beijing. There are now plans to extend it to 
other cities in China and Malaysia. 
 
The large-scale research shows that the approach is highly effective. The cost 
and benefit modelling is still taking place, but the smaller-scale Australian 
modelling showed a net benefit of AUD $16,000 a year for each participant due 
to improved health and lower use of services. What is more, the programme has 
improved the participants’ quality of life, with increased social networks and 
greater psychological well-being.  
 
7. Medical tourism 
 
Medical tourism is amongst a range of niche markets that will likely be fuelled 
by the health demands of ageing populations. The term usually refers to patients 
travelling to other countries in pursuit of medical services, often incorporating 
leisure activities.  
 
The industry is still poorly defined. Services can range from ‘wellness’ treatment 
(e.g., massage and acupuncture) to elective procedures (e.g., cosmetic, dental) 
and specialist and medically necessary healthcare (e.g., chemotherapy). The 
main Asian destinations are thought to be India, Korea, Malaysia, Singapore and 
Thailand. Those liable to benefit may not only include the health providers 
themselves but also those involved in travel and accommodation, conference and 
media, financial products and insurance, website portals and brokering agencies. 
 
The lack of robust definitions and or standard data means that estimates of the 
size of the industry range from an annual 60,000 to 50 million patients 
worldwide (Ehrbeck et al., 2008; Lunt et al., 2011). But most sources agree that 
the market is growing rapidly. Even in Australia, which was estimated to have 
received only around 13,000 medical travellers in 2010, the rate of growth of 
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this figure is thought to be 14 per cent per year, compared to 2 per cent for all 
tourists (Deloitte Access Economics, 2011).  
 
The pace of growth is perhaps unsurprising given the increases in demand from 
wealthier and older populations coupled with limits on supply from health 
systems, which leave some procedures uncovered or rationed by way of long 
waiting periods. The demand will likely intensify. For example, if China had the 
same levels of hip replacement per person over the age of 65 as the OECD, by 
2050 it would translate to over three million hip replacements per year. 
 
Unlocking the potential of this market depends on several factors. Currently, 
waiting time and cost are important reasons for travel. A hip replacement in 
Thailand costs about a quarter of what it does in the United States, and half of 
the cost in Australia (Figure 5.A). Yet, a survey by Ehrbeck et al. (2008) reveals 
that only 28 per cent of those who travelled for treatment did so because of cost 
and time considerations (Figure 5.B). The rest cared more about superior quality 
or medical technology available in the destination country. This finding is 
encouraging for countries with medium levels of cost but advanced medical 
facilities, such as Japan and Australia.  
 
Figure 5. Costs and drivers of medical tourism 
A. Cost comparison of hip replacement surgery (US$) 
 
B. Medical tourists segmented by reasons for activity 
 
Source: Ehrbeck et al, 2008; Lunt et al, 2011; Note: Cost of surgery is based on 2010/2011 values  
 
One issue with gauging quality is that despite an accreditation scheme, there is 
scant data on quality of care and little in the way of disclosure about 
complication rates, or, indeed, international regulation to cope with such 
complications. Without regulatory infrastructure agreed at a regional level, 
health insurers may also be wary of covering travel and treatment in other 
countries, even if the total cost may be lower. The limitations suggest that 
providers, insurers and governments need to approach this area constructively if 
they are to benefit from such trade.  
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Box 3. CEPAR research spotlight: Delivering services by mobile phone 
 
Innovative delivery models can improve access and reduce costs of healthcare. 
For example, some health needs can be addressed by use of mobile phone 
technology, especially in countries with low healthcare infrastructure. This is the 
concept behind mHealth (and eHealth via the internet), where patients can have a 
medical consultation, treatment, diagnosis, referral and counselling from 
registered physicians, all by mobile phone. Pradeep Ray, a CEPAR Associate 
Investigator, has looked at perceptions of quality of mHealth (Akter et al. 2010) 
and is undertaking work on acceptance of such delivery models in Bangladesh 
and India. Mobile and internet technology in healthcare will be important for 
both developing and developed countries as population ageing takes place. 
 
8. Conclusion 
 
This final research brief in a three-part series looked at healthcare systems across 
Asia. It described how the development of healthcare systems will be shaped by 
demographic change. As Asians become wealthier and older they will demand 
greater levels of health coverage, which will depend not only on the breadth of 
the eligible population but also on the scope of the benefits and level of costs 
covered of those who are insured.  
 
To ensure that this does not result in disproportionate cost growth, governments 
will have to consider various macro, micro, and demand-side measures. 
Healthcare demand provided by the state, out-of-pocket costs and private 
insurance is already substantial and population ageing will increase this further, 
creating market opportunities for private sector insurers, providers, and the 
medical tourism market.  
 
At the level of the macro-economy, stronger welfare provision has the potential 
to rebalance growth in the region – where individuals can pool income and 
health risks and have less need for excessive precautionary savings. 
 
The briefs covered retirement and healthcare systems, but there are of course 
other fields that invite analysis. For example, long-term aged care is a yet 
undeveloped policy area in Asia, particularly among low and middle-income 
countries, but one that will also require attention (Box 4; see also Box 2 in the 
first brief in this series). 
 
As the first brief in this series notes, the Asian century will also be the ageing 
century – an important concept to grasp for countries, institutions, and 
individuals wishing to understand their place in its future and to take advantage 
of the opportunities it can offer ■ 
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Box 4. CEPAR research spotlight: Disability & functional limitations of older people 
 
Physical disability and functional limitation are known to increase with age. But 
there is a dearth of relevant data for emerging Asian countries. CEPAR Chief 
Investigator, Robert Cumming, with other colleagues (Hairi et al., 2010), 
collected such data for the rural population in Malaysia.   
 
The study involved two levels of assessment: (1) self-reported physical 
disability, based on whether the individual had problems with one in five, six, or 
ten Activities of Daily Living (ADLs); and (2) functional disability, based on 
practical tests of functional limitation such as walking and sitting.  
 
They find that half of those aged 75+ reported needing help in at least one of the 
10 ADLs, and that ethnic Indians had greater levels of physical disability. 
Comparing results with international studies reveals that developing countries 
such as Malaysia have higher levels of disability among the old (Figure 6). This 
may relate, firstly, to socio-demographic differences: older people in rural 
Malaysia have lower levels of education and remain active in physically 
demanding, farming jobs.  Secondly, formal care in Malaysia is accessible only 
to the wealthy or the destitute, so more disabled older people live in the 
community than is the case in developed countries. Institutions were not included 
in the Malaysian data, so sampling differences may exist between studies.  
 
Collecting such data is an important step in designing support for care-giving 
arrangements as well as gauging the likely utilisation of healthcare. Professor 
Cumming is also involved with a major multidisciplinary study of ageing in  
Malaysia (MELoR – Malaysian Elders Longitudinal Research). 
 
Figure 6. Prevalence of needing help with one in five ADLs for population 65+ 
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